History

2017


2016

  • October
    • Entered a product licensing and marketing agreement with Eurofarma Laboratorios S.A. for farletuzumab in Latin America
  • September
    • Entered into a sponsored research and collaboration with Fox Chase Cancer Center to develop human organoid systems from primary human tumors to study the effects of tumor immune suppression to improve patient selection of Morphotek first-in-class experimental therapies.
  • April
    • Announced publication of Phase 3 results from MORAb-003-004 trial in platinum-sensitive ovarian cancer patients.
  • March
    • Entered collaboration with Areva Med on lead-212 targeted alpha therapies.
  • February
    • Entered collaboration with Mayo Clinic to apply its folate receptor alpha diagnostic assays in a Phase 2 clinical trial in triple-negative breast cancer.
  • January
    • Selected Cryoport to manage cold chain logistics.

2015

  • December
    • Announced Phase 1 results from MORAb-022-001 trial in healthy subjects and patients with mild-to-moderate rheumatiod arthritis.
    • Entered collaboration with researchers at the University of Wisconsin-Madison to study the immunosuppressive effects of CA125 tumor antigen on immune-based therapies for ovarian cancer, including farletuzumab.
  • November
    • Initiated amatuximab ARTEMIS study in first-line, unresectable, malignant pleural mesothelioma patients.
    • Entered collaboration with researchers at the University of Gothenburg to develop a farletuzumab alpha-particle radioimmunotherapy for ovarian cancer.
    • Signed license agreement with Blaze Bioscience Inc. for the development of a novel oncology imaging technology using chlorotoxin peptide platform.
  • October
    • Presented preclinical findings at ESGO 19 on the potential immuno-suppressive effects of the CA125 tumor antigen on farletuzumab, an investigational anti-folate receptor alpha antibody.
  • March
    • Initiated farletuzumab clinical study in patients with first-relapsed, platinum-sensitive ovarian cancer with low levels of CA125 tumor antigen.
  • January
    • Recognized as Top-25 Life Sciences Company in the greater Philadelphia area.

2014

  • July
    • Entered into Research Option Agreement with Sorrento Therapeutics to develop antibody drug conjugates.
    • Entered into research collaboration with Stealth Biologics to develop deimmunized therapeutic proteins.
  • January
    • Granted orphan drug status by European commission for amatuximab for the treatment of malignant mesothelioma.

2013

  • October
    • Initiated a Phase 1 clinical study of ontuxizumab in pediatric cancers.
  • June
    • Initiated a Phase 1 clinical study of MORAb-066 in breast, pancreatic, colorectal and non-small cell lung cancer.
    • Received Governor's IMPACT award for entrepreneurship in Pennsylvania.
  • January
    • Pilot Plant awarded facility of the year for its design and innovative infrastructure.

2012

  • November
    • Granted orphan status by FDA for use of amatuximab in malignant pleural mesothelioma.
  • August
    • Initiated a global Phase 2 study of MORAb-004 in patients with metastatic soft tissue sarcoma.
    • Opened 60,000 sq. ft. state-of-the-art GMP pilot plant to support manufacturing of biopharmaceutical products.
  • May
    • Won Prestigious Innovation Award for assay development from The American Association of Pharmaceutical Scientists.
  • April
    • Initiated Phase 2 Clinical Study of MORAb-004 in chemorefractory metastatic colorectal cancer.
  • March
    • Formed a partnership with Biocare Medical to develop and commercialize an in vitro diagnostic immunohistochemical (IHC) kit to detect folate receptor alpha (FRA) expression in formalin-fixed paraffin-embedded (FFPE) malignant tissues. The kit will be available in the U.S. as a Class I IHC IVD assay and is CE marked for use in Europe.
    • Completed enrollment of its 1100-patient Phase 3 pivotal trial FAR-131 in 1st-relapsed platinum-sensitive ovarian cancer.
  • January
    • Entered into agreement with Fox Chase Cancer Center to acquire clinical samples essential for the development and validation of companion diagnostic assays.

2011

  • June
    • Initiated Phase 2 clinical study of farletuzumab in first-line non-small cell adenocarcinoma of the lung.
  • May
    • Initiated Phase 2 clinical study of MORAb-004 in metastatic melanoma.
  • April
    • Announced acquisition of tumor-targeting platform from Transmolecular Inc.
    • Received Beacon Award from CancerCare, a patient advocacy group.
    • Received additional funding from the U.S. Department of Defense to support development of therapeutic antibodies to combat biowarfare agents.
  • March
    • Signed agreement with Biocare Medical to develop and commercialize a diagnostic kit for folate receptor alpha-positive malignant tissues.

2010

  • November
    • Initiated a Sponsored Research Agreement with Hokkaido University to evaluate amatuximab in advanced pancreatic cancer.
  • October
    • Received funding from the U.S. Department of Defense to support development of therapeutic antibodies to combat microbial bioweapons.
  • September
    • Morphotek and Human Genome Sciences select a therapeutic monoclonal antibody to advance into development.
  • June
    • Initiated MORAb-022 clinical study in Europe for the treatment of inflammatory disease.
  • May
    • Announced appointment of Dr. Joye Bramble as Vice President of Pilot Plant Operations.
  • April
    • Morphotek and Champions Biotechnology announced an agreement to use Biomerk Tumorgraft platform to evaluate therapeutic antibodies for cancer.
  • March
    • Broke ground for a pilot plant to manufacture biological-based drugs.

2009

  • October
    • Completed a licensing deal with Centocor Ortho for exclusive rights to a therapeutic monoclonal antibody.
  • September
    • Awarded funding from U.S. Department of Defense to develop therapeutic antibodies against biowarfare toxins.
  • August
    • Entered an evaluation and option agreement with Cancer Innovations, Inc. for therapeutic monoclonal antibodies.
  • July
    • Entered a Research Collaboration Agreement with Synageva BioPharma Corporation to develop potential treatments for cancer and infectious disease.
  • June
    • Announced FDA acceptance of Investigational New Drug Application for MORAb-004, a monoclonal antibody for the treatment of cancer.
  • May
    • Entered a Manufacturing Services Agreement with Lonza Group LTD.
  • March
    • Entered a collaboration with Human Genome Sciences to discover, develop and commercialize antibodies for oncology and immunology.
    • Announced FDA Special Protocol Assessment (SPA) for Phase 3 trial evaluating farletuzumab in relapsed ovarian cancer.
    • Initiated MORAb-009 Phase 2 study in 1st-line treatment of mesothelioma
  • January
    • Signed collaboration with University Hospital Heidelberg to develop therapeutic antibodies to treat cancer.

2008

  • December
    • Signed collaboration with University of Pennsylvania to develop antibodies to targets present in hypoxic regions of tumors to treat cancer.
  • November
    • Received funding from U.S. Department of Defense to support development of therapeutic antibodies to treat against biowarfare pathogens.
  • September
    • Signed agreement with Pivotal Biosciences, Inc. to access new antibody technology to improve therapeutic activity.
  • August
    • Opened clinical sites in Europe to expand Phase 2 trial of MORAb-009 in 1st-line pancreatic cancer.
    • Signed collaboration/license agreement with the National Cancer Institute to develop antibodies to a prostate cancer target.
  • July
    • Morphotek Executive, Rodney Dausch, named Small Company CFO of the Year in the Greater Philadelphia Region.
  • June
    • Received funding from U.S. Department of Defense to develop antibodies to treat against infectious disease agents.
  • May
    • Established collaboration with the National Institute of Allergy and Infectious Diseases to develop therapeutic antibodies to treat against infectious pathogens.
  • April
    • Received orphan status from European regulatory authorities for farletuzumab in ovarian cancer and MORAb-009 in pancreatic cancer.
  • March
    • Signed agreement with Human Monoclonal International Inc to license and develop an antibody to treat cancer.
  • January
    • Signed collaboration agreement with the Ludwig Institute to validate disease targets.

2007

  • December
    • Initiated MORAb-009 randomized, controlled Phase 2 study in 1st-line pancreatic cancer.
  • October
    • Received funding from the National Institute of Allergy and Infectious Diseases to develop therapeutic antibodies against biowarfare agents.
  • September
    • Received funding from the U.S. Department of Defense to develop therapeutic antibodies against biowarfare agents.
  • June
    • Morphotek CEO Nicholas Nicolaides named Ernst & Young Entrepreneur Of The Year® 2007 award winner in Greater Philadelphia Region.
  • May
    • Signed Development and Clinical Supply Agreement with CMC Biopharmaceuticals A/S for therapeutic antibody to treat melanoma.
  • April
    • Acquired by Eisai Corporation.
  • February
    • Obtained exclusive license from Micromet for antibody to treat melanoma and other cancers.
    • President and CEO Nicholas Nicolaides honored as top-20 Scientist by R&D Directions.

2006

  • November
    • Selected as one of the region's top-three fastest-growing companies by Philadelphia 100®.
  • October
    • Raised $40 million to advance its antibody pipeline.
  • June
    • Initiated Phase 2 clinical trial for MORAb-003 in ovarian cancer.
  • February
    • FDA Accepted IND Application for MORAb-009.

2005

  • December
    • Signed exclusive license agreement with the National Cancer Institute (MORAb-009).
  • September
    • Invitrogen Corporation acquired cell line optimization service business.
  • February
    • FDA accepted IND Application for MORAb-003.
    • Nicholas Nicolaides, Morphotek’s President & CEO, was a “40 Under 40” honoree. The award is based on a recipient's commitment to professional excellence and community involvement.
  • January
    • Awarded development grant by NCI.
    • Named “The Company to Watch” by BioExecutive International magazine.

2004

  • December
    • Signed exclusive license agreement with the Ludwig Institute for Cancer Research (MORAb-004).
  • November
    • Named “2004 Technology Company of the Year” by the Greater Philadelphia Chamber of Commerce. This award is based on a company’s achievements, vitality, creativity and impact on their industry.
  • September
    • Signed CRADA with USAMRIID.
  • July
    • Signed cross-license agreement with Protein Design Labs.
  • March
    • Awarded the distinguished “Alumni Award” by the Ben Franklin Technology Partners of Southeastern Pennsylvania.
  • February
    • Raised $26 million in Series C funding.

2003

  • October
    • Signed manufacturing agreement with Baxter Healthcare.

2002

  • September
    • Awarded Pennsylvania Opportunity Grant by PA Governor Mark Schweiker.
  • July
    • Awarded U.S. Army grant.
  • May
    • Expanded operations and relocated to 41,000 sq. ft. facility in Exton, PA.
  • April
    • Signed Research Agreement with the Ludwig Institute for Cancer Research (MORAb-003).
  • March
    • Named “Biotech Company of the Year” by Ben Franklin Technology Partners of Southeastern Pennsylvania, recognizing the exceptional management team, prospects for achieving product commercialization, and significant growth potential.
  • February
    • Signed Research Agreement with the Wistar Institute.
    • Received the “People’s Choice” award at the annual Early Stage East Bio-Life-Tech Conference.

2001

  • August
    • Raised $10 million in Series B funding.
  • February
    • Awarded “Ben Franklin Emerging Fund” by Ben Franklin Technology Partners of Southeastern Pennsylvania.

2000

  • November
    • Established Scientific Advisory Board.
  • July
    • Established Board of Directors.
  • May
    • Founded by Drs. Luigi Grasso, Nicholas Nicolaides and Phillip Sass.